Compare STN & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STN | QGEN |
|---|---|---|
| Founded | 1954 | 1986 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 9.0B |
| IPO Year | 2005 | 1998 |
| Metric | STN | QGEN |
|---|---|---|
| Price | $72.21 | $50.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $49.02 |
| AVG Volume (30 Days) | 270.0K | ★ 4.8M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | 0.95% | ★ 5.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.97 | $2.18 |
| Revenue Next Year | $5.63 | $5.03 |
| P/E Ratio | $28.96 | ★ $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.35 | $32.53 |
| 52 Week High | $111.02 | $57.82 |
| Indicator | STN | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 71.26 |
| Support Level | $71.90 | $49.37 |
| Resistance Level | $73.03 | $50.34 |
| Average True Range (ATR) | 1.57 | 1.01 |
| MACD | 0.49 | 0.21 |
| Stochastic Oscillator | 87.77 | 88.55 |
Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. It offers services through the following business operating units; Environmental Services, Infrastructure, Water, Buildings, and Energy & Resources. Maximum revenue is derived from its Infrastructure business unit, which is engaged in evaluating, planning, and designing infrastructure solutions for transportation, community development, and urban spaces. The company's reportable segments are the United States, which derives maximum revenue, Canada, and Global. These segments provide consulting in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics services in the area of infrastructure and facilities.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).